Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

On September 23, 2024, Judge Kleeh of the Northern District of West Virginia denied Regeneron Pharmaceuticals, Inc.’s ...

Regeneron spent $5 billion repurchasing shares from Sanofi in May 2020 and $900 million repurchasing global rights to Libtayo in July 2022, yet a windfall from sales of its Covid antibody cocktail as ...

Biogen will retain its commercial rights to the biosimilars already brought to market, as well as copycat version of Bayer's age-related macular degeneration blockbuster Eylea (aflibercept ...

Amgen (NASDAQ: AMGN) stock is up 13% this year but has struggled to break out above a tight trading range in recent months. Despite a string of solid earnings reports from the biotechnology giant ...

Amgen is posting strong growth across its diversified-medicines portfolio. A new weight-loss drug candidate could be a game-changer for the company. Trading at 17 times earnings, the stock offers ...

Bernstein started coverage of Eli Lilly (NYSE:LLY), Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) with outperform ratings. The investment firm said its bullish ratings on Gilead and Amgen ...

Amgen Inc. (AMGN), headquartered in Thousand Oaks, California, discovers, develops, manufactures, and delivers human therapeutics. With a market cap of $174.4 billion, the company focuses on ...

On Wednesday, Goldman Sachs reiterated its Conviction Buy rating on Amgen (NASDAQ:AMGN), maintaining a price target of $369.00. The endorsement follows Amgen's progress through a year filled with ...

Amgen today is the biggest biotechnology company in the world, but its plush headquarters, global reach and tens of thousands of employees belie its humble origins. Founded in 1980 as Applied ...